SLC5A2 and myocardial ischemia: Additionally, patients without IHD demonstrated significantly higher usage of angiotensin receptor blockers (ARBs), sodium–glucose cotransporter-2 (SGLT2) inhibitors, and statins compared to those with IHD (Table 1).